WO2009056603A1 - Capsule destinée à contenir des formulations de principes actifs pharmaceutiques - Google Patents

Capsule destinée à contenir des formulations de principes actifs pharmaceutiques Download PDF

Info

Publication number
WO2009056603A1
WO2009056603A1 PCT/EP2008/064743 EP2008064743W WO2009056603A1 WO 2009056603 A1 WO2009056603 A1 WO 2009056603A1 EP 2008064743 W EP2008064743 W EP 2008064743W WO 2009056603 A1 WO2009056603 A1 WO 2009056603A1
Authority
WO
WIPO (PCT)
Prior art keywords
amino
phenyl
quinazoline
chloro
capsule
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2008/064743
Other languages
German (de)
English (en)
Inventor
Eduard Balthes
Johannes Geser
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim International GmbH
Original Assignee
Boehringer Ingelheim International GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim International GmbH filed Critical Boehringer Ingelheim International GmbH
Publication of WO2009056603A1 publication Critical patent/WO2009056603A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A61K9/4825—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0028—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
    • A61M15/003—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using capsules, e.g. to be perforated or broken-up
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2202/00—Special media to be introduced, removed or treated
    • A61M2202/06—Solids
    • A61M2202/064—Powder

Definitions

  • the invention relates to a capsule for receiving pharmaceutical active ingredient formulations as a primary packaging component of a packaging unit and a use thereof.
  • Capsules with pharmaceutical drug formulations are widely used in the therapy and diagnosis of diseases.
  • the capsules may be administered orally or used in certain medical devices, such as powder inhalers.
  • the capsules consist of two parts, namely a capsule body and a capsule cap, which are pushed telescopically into one another. Also multi-part capsules are known.
  • Capsule material used for primary packaging of pharmaceutical products is used for primary packaging of pharmaceutical products.
  • the gelatin capsule also has significant disadvantages, among other things, it will become brittle at low ambient humidity.
  • BSE bovine spongiform encephalopathy
  • Challenge of gelatin as a product of animal origin in the manufacture of capsules If necessary, gelatine must be replaced by alternative materials.
  • HPMC hydroxypropyl methylcellulose
  • the aim is to use as many plastics as possible, which, among other things, have a very low water content, in order to even introduce as little water as possible into the packaging.
  • the very low water absorption capacity is increasingly proving to be a decisive disadvantage compared to the highly water-absorptive gelatin capsule.
  • the remaining packaging materials such as films, bottles and the like, as well as by the product itself moisture is registered in a primary packaging. This moisture is trapped in the primary packaging after the packaging process and can only diffuse out slowly.
  • the relative humidity increases considerably and endangers the product. A decomposition, a clumping or recrystallization of powders, etc. may be the result.
  • WO 2006/122790 A1 discloses a capsule for packaging inhalation formulations in which at least a cavity is enclosed by a wall. At least part of the wall has a polymer composition containing at least one adsorbent.
  • the adsorbent for example silica gel, drying or moisture or water adsorbing clays, aluminosilicates such as zeolites or bentonites, molecular sieves, activated carbon, ⁇ rdalkalioxide, calcium sulfate or mixtures thereof, is attached to the polymer composition.
  • the adsorbent also has an influence on the mechanical properties of the polymer composition.
  • Packaging components are conditioned, the Heidelbergsprozes ⁇ is provided even in a conditioned climate and / or primary packaging with desiccant-equipped secondary packaging (pouches) are surrounded.
  • Such a packaging unit is described for example in the form of a case box with blister cards in EP 0 479 282 A1.
  • EP 1 100 474 A1 discloses e.g. Plastic capsules, which consist of a capsule body and a capsule cap, both made of the same non-water-soluble, hydrophobic plastic and which can be interconnected so that a stable, closed cavity of defined volume is formed.
  • the plastic is polyethylene.
  • Such capsules are suitable for use in, inter alia Powder inhalers determined.
  • powder inhalers may be mentioned are: HandiHaler ®, as has been disclosed, for example 483 in the EP 1 342 Spinhaler ®, Rotaha- ler ®, Aerolizer ®, Plowcaps ®, Turbo ⁇ pin ®, AIR DPI ®, Orbital ® or Directhaler ® so such as inhalers, which, inter alia, in the
  • the object is achieved in that the capsule is completely made of a water absorptive material and is conditioned at a low relative humidity.
  • the material from which the capsule or its wall is made is itself an adsorbent and is not composed of a base material and an adsorbent.
  • the capsule is made of the water-absorptive material which is conditioned at a low relative humidity, ie has a relatively residual moisture due to the treatment, the capsule itself absorbs most of the moisture in the packaging ("moisture sink"). ) and thus lowers the moisture in the product.
  • the conditioning of this capsule material before the packaging process at low humidity serves to maximize the water absorption capacity and thus the absorber function.
  • the starting moisture in the packaging unit can thereby be drastically reduced. Furthermore, the starting moisture can be determined and controlled by a suitable choice of conditioning.
  • polyamide Ph-6, PA-6.6
  • cellulose acetate As a water-absorptive material in particular polyamide (Ph-6, PA-6.6) or cellulose acetate is particularly advantageous. These plastics have an over other plastics extremely high water absorption and are therefore particularly suitable for use as a water absorber.
  • the water-absorptive material As a water-absorptive material, gelatin which has been previously heated is preferably suitable. Sufficient heating is beneficial in terms of preventing BSE (bovine spongiform encephalopathy).
  • the water-absorptive material has a water absorption capacity of greater than or equal to 1.5% under standard conditions according to ISO 62. This is achieved in particular by polyamides. Water absorption in the range above 3%, preferably up to 3%, can be achieved with these materials.
  • the water-absorptive material is conditioned at a relative humidity of less than or equal to 20%. This can already be achieved an effective moisture reduction. In order to achieve a particularly effective moisture reduction, the water-absorptive material is conditioned at a relative humidity of less than or equal to 10%.
  • the water-absorptive material is conditioned as a bulk product.
  • the starting value in the packaging can be determined specifically.
  • the water-absorptive material is conditioned by a single conditioning step. Since ⁇ by a strong simplification of the packaging process can be realized.
  • the capsule material within the packaging unit is the only water-absorptive material. This stabilizes low moisture levels in the packaging over a long period of time without further aids such as pouches or desiccants.
  • An advantageous use of the capsule provides the use as a primary packaging for receiving particularly moisture-sensitive drugs, such as finely powdered pharmaceutical agents, before. Especially with such inhalants, moisture absorption is important.
  • W is a pharmacologically active agent and (for example) selected from the group consisting of betamimetics, anticholinergics, corticosteroids, PDE4 inhibitors, LTD4 antagonists, EGFR inhibitors, dopamine agonists, HIV antihistamines, PAF Antagonists and PI3 kinase inhibitors.
  • a pharmacologically active agent selected from the group consisting of betamimetics, anticholinergics, corticosteroids, PDE4 inhibitors, LTD4 antagonists, EGFR inhibitors, dopamine agonists, HIV antihistamines, PAF Antagonists and PI3 kinase inhibitors.
  • two- or three-fold combinations of W can be combined and used for application in the device according to the invention. Exemplary combinations of W were:
  • W represents a betamimetics combined with an anticholinergic, corticosteroids, PDE4 inhibitors, EGFR inhibitors or LTD4 antagonists,
  • W represents an anticholinergic agent combined with a betamimetics, corticosteroids, PDE4 inhibitors,
  • W represents a corticosteroid combined with a PDE4 inhibitor
  • EGFR inhibitor or LTD4 antagonist - W represents a PDE4 inhibitor combined with an EGFR inhibitor or LTD4 antagonist
  • W represents an EGFR inhibitor combined with a LTD4 antagonist.
  • Suitable betamimetics are preferably compounds which are selected from the group consisting of albuterol, arformoterol, bambuterol, bitolertrol, broxaterol, carbuterol, clenbuterol, fenoterol, formermol, hexoprenaline, ibuterol, isoetharine, isoprenaline , Levosalbutamol, Mabuterol, Meluadrine, Metaproterenol, Orciprenaline, Pirbuterol, Procaterol, Reproterol, Rimiterol, Ritodrine, Salmefamol, Salmeterol, Soterenol, ⁇ ulphonterol, Terbutaline, Tiaramide, Tolubuterol, Zinterol, CHF-1035, HOKU-81, KUL -1248 and
  • N-adamantan-2-yl-2 - (3 - ⁇ 2- [2-hydroxy-2- ⁇ 4-hydroxy-3-hydroxymethylphenyl) -ethylamino] -propyl ⁇ -phenyl) -acetamide optionally in the form of their racemates, enantiomers, diastereomers and optionally in the form of their pharmacologically acceptable acid addition salts, solvates or hydrates.
  • the acid addition salts of the betamimetics selected from the group consisting of hydrochloride, hydrobromide, hydroiodide, hydrosulfate, hydrophosphate, hydromethanesulfonate, hydronitrate, hydromaleate, hydroacetate, hydrocitrate, hydrofumarate, hydrotartrate, hydroxalate, hydrosuccinate, hydrobenzoate and hydro-p Toluenesulfonate.
  • Preferred anticholinergic compounds are compounds which are selected from the group consisting of tiotropium salts, preferably the bromide salt, oxitropium salts, preferably the bromide salt, flutropium salts, preferably the bromide salt, ipratropium salts, preferably the bromide salt, glycopyrronium salts the bromide salt, trospium salts, preferably the chloride salt, tolterodine.
  • tiotropium salts preferably the bromide salt, oxitropium salts, preferably the bromide salt, flutropium salts, preferably the bromide salt, ipratropium salts, preferably the bromide salt, glycopyrronium salts the bromide salt, trospium salts, preferably the chloride salt, tolterodine.
  • tiotropium salts preferably the bromide salt, oxitropium salts, preferably the bromide salt, flutropium salts, preferably the bromide salt,
  • the above genann ⁇ th salts may preferably contain chloride, bromide, iodide, sulfate, phosphate, methanesulfonate, nitrate, maleate, acetate, citrate, fumarate, tartrate , Oxalate, succinate, benzoate or p-toluenesulfonate, with chloride, bromide, iodide, sulfate, methanesulfonate or p-toluenesulfonate being preferred as counterions.
  • the chlorides, bromides, iodides and methanesulfonates are particularly preferred.
  • preferred anticholinergics are selected from the salts of the formula AC-I
  • X is a singly negatively charged anion, preferably an anion selected from the group consisting of fluoride, chloride, bromide, iodide, sulfate, phosphate, methanesulphonate, nitrate, maleate, acetate, citrate, fumarate, tartrate, oxalate, succinate, Benzoate and p-toluenesulfonate, preferably a single negatively charged anion, more preferably an anion selected from the group consisting of fluoride, chloride, bromide, methanesulfonate and p-toluenesulfonate, most preferably bromide, optionally in the form of their racemates, enantiomers or hydrates.
  • anion selected from the group consisting of fluoride, chloride, bromide, iodide, sulfate, phosphate, methanesulphonate, nitrate, maleate, acetate, citrate,
  • X - may have the meanings given above.
  • Further preferred anticholinergics are selected from the salts of the formula AC-2
  • R is either methyl or ethyl and wherein X - may have the meanings given above.
  • the compound of the formula AC-2 may also be present in the form of the free base AC-2-base.
  • Preferred corticosteroids are compounds which are selected from the group consisting of beclomethasone, betamethasone, budesonide, Buxtococort, ciclesonide, deflazacort, dexamethasone, etipredanol, flunisolide, fluticasone, loteprednol, mometasone,
  • Examples of possible salts and derivatives of the steroids may be: alkali metal salts, such as, for example, sodium or potassium salts, sulphobenzoates, phosphates, isonotinotinates, acetates, dichloroacetates, propionates, dihydrogenphosphates, palmitates, pivalates or furoates.
  • alkali metal salts such as, for example, sodium or potassium salts, sulphobenzoates, phosphates, isonotinotinates, acetates, dichloroacetates, propionates, dihydrogenphosphates, palmitates, pivalates or furoates.
  • PDE4 inhibitors compounds which are selected from the group consisting of enprofylline, theophylline, roflumilase, ariflo (cilomilast), tofimilast, pumafentrin, lirilmast, arofylline, atizoram, D-4418, bayonitrile, are preferably used here.
  • the pressure additi ⁇ onssalze of PDE4 are preferred according inhibitors selected from the group consisting of hydrochloride, hydrobromide, hydroiodide, rosulfat hydrauli-, hydrophosphate, hydromethanesulphonate, Hydronit- rat, Hydromaleat, hydroacetate, Hydrocitrat, Hydrofumarat, Hydrotartrat, Hydrooxalat, Hydrosuccinat, Hydrobenzoat and hydro-p-toluenesulfonate.
  • inhibitors selected from the group consisting of hydrochloride, hydrobromide, hydroiodide, rosulfat hydrauli-, hydrophosphate, hydromethanesulphonate, Hydronit- rat, Hydromaleat, hydroacetate, Hydrocitrat, Hydrofumarat, Hydrotartrat, Hydrooxalat, Hydrosuccinat, Hydrobenzoat and hydro-p-toluenesulfonate.
  • Preferred LTD4 antagonists here are compounds selected from the group consisting of montelukast, pranlukast, zafirlukast, MCC-847 (ZD-3523), MN-OOI, MEN-91507 (LM-1507), VUF -5078, VUF-K-8707, L-733321 and - 1 - (((R) - (3 - ⁇ 2 - (6,7-di-fluoro-2-quinolinyl) -1-phenyl) -3- (2- (2-hydroxy-2-propyl) phenyl) thio ) methyl cyclopropane-acetic acid,
  • these acid addition salts are selected from the group consisting of hydrochloride, hydrobroride, hydroiodide, hydrosulfate, hydrophosphate, hydromethanesulfonate, hydronitrate, hydromaleate, hydroacetate, hydrocitrate, hydrofumarate, hydrotartrate, hydroxalate, hydrosuccinate, hydrobenzoate and hydro-p - Toluenesulfonate.
  • salts or derivatives which BiI- d ü ng the LTD4 antagonists optionally are able to be for example: alkali metal salts such as sodium or potassium salts, alkaline earth metal salts, sulphobenzoates, phosphates, isonicotinates, acetates, propionitrile nate, dihydrogen phosphates, Palmitate, pivalate or furoate.
  • alkali metal salts such as sodium or potassium salts, alkaline earth metal salts, sulphobenzoates, phosphates, isonicotinates, acetates, propionitrile nate, dihydrogen phosphates, Palmitate, pivalate or furoate.
  • Preferred EGFR inhibitors are compounds selected from the group consisting of cetuximab, trastuzumab, ABX-EGF, Mab ICR-62 and - 4- [(3-chloro-4-fluorophenyl) amino] -6- ⁇ [4- (morpholin-4-yl ) -1-oxo-2-buten-1-yl] amino ⁇ -7-cyclopropylmethoxyquinazoline
  • these acid addition salts are selected from the group consisting of hydrochloride, hydrobromide, hydroiodide, hydrosulfate, hydrophosphate, hydromethanesulfonate, hydronitrate, hydroraaleate, hydroacetate, hydrocitrate, hydrofumarate, hydrotartrate, hydroxalate, hydrosuccinate, hydrobenzoate and hydro p-toluenesulfonate.
  • Preferred dopamine agonists are compounds selected from the group consisting of bromocriptine, cabergoline, alpha-dihydroergocryptine, lisuride, pergolide, pramipexole, rooxinol, ropinirole, talipexol, terguride and viozan, optionally in the form of theirs Racemates, enantiomers, diastereomers and optionally in the form of their pharmacologically acceptable acid addition salts, solvates or hydrates.
  • these acid addition salts are selected from the group consisting of hydrochloride, hydrobromide, hydroiodide, hydrosulfate, hydrophosphate, hydromethanesulfonate, hydronitrate, hydromaleate, hydroacetate , Hydrocitrate, hydrofumarate, hydrotartrate, hydrooxalate, hydrosuccinate, hydrobenzoate and hydro-p-toluenesulfonate.
  • Hl-antihistamines here preferably compounds are used, which are selected from the group consisting of epinastine, cetirizine, azelastine, fexofenadine, levocabastine, loratadine, mizolastine, ketotifen, emedastine, dimetindene, clemastine, bamipin, Cexch- lormeniramine, pheniramine, doxylamine, chlorophenoxamine, dimenhydrinate, diphenhydramine, promethazine, ebastine, desoratidin and meclocine, optionally in the form of their racemates, enantiomers, diastereomers and optionally in the form of their pharmacologically acceptable acid addition salts, solvates or hydrates.
  • these acid addition salts are selected from the group consisting of hydrochloride, hydrobromide, hydroiodide, hydrosulfate, hydrophosphate, hydromethanesulfonate, hydronitrate, hydromaleate, hydroacetate, hydrocitrate, hydrofumarate, hydrotartrate, hydroxalate, hydrosuccinate, hydrobenzoate and hydro-p-toluenesulfonate ,
  • substance formulations or substance mixtures all inhalable compounds are used, such as e.g. also inhalable macromolecules, as disclosed in EP 1 003 478.
  • substances, substance formulations or substance mixtures are used for the treatment of respiratory diseases, which are used in the inhalation field.
  • the compound may be derived from the group of derivatives of ergot alkaloids, the triptans, the CGRP inhibitors, the phosphodiesterase V inhibitors, optionally in the form of their racemates, enantiomers or diastereomers, optionally in the form of their pharmacologically acceptable acid addition salts, their solvates and / or hydrates.
  • results of the simulation show that the starting moisture can be controlled and controlled with the help of a single - the dominant - component of a packaging. This option represents a significant reduction in the cost of packaging and its control process.
  • the simulation calculation was carried out on a currently installed blister system.
  • the capsule used in this case was replaced by a PA-capsule.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Anesthesiology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention concerne une capsule destinée à contenir des formulations de principes actifs pharmaceutiques, en tant que constituant d'emballage primaire d'une unité d'emballage. Ladite capsule se compose entièrement d'un matériau apte à absorber l'eau et est conditionnée à un taux d'humidité relativement bas.
PCT/EP2008/064743 2007-11-02 2008-10-30 Capsule destinée à contenir des formulations de principes actifs pharmaceutiques Ceased WO2009056603A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102007052871.1 2007-11-02
DE200710052871 DE102007052871A1 (de) 2007-11-02 2007-11-02 Kapsel zur Aufnahme von pharmazeutischen Wirkstoffformulierungen

Publications (1)

Publication Number Publication Date
WO2009056603A1 true WO2009056603A1 (fr) 2009-05-07

Family

ID=40189269

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2008/064743 Ceased WO2009056603A1 (fr) 2007-11-02 2008-10-30 Capsule destinée à contenir des formulations de principes actifs pharmaceutiques

Country Status (2)

Country Link
DE (1) DE102007052871A1 (fr)
WO (1) WO2009056603A1 (fr)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE605541C (de) * 1926-05-09 1934-11-13 August Adolf Dulitz Verfahren zur Herstellung von Schrumpfkapseln aus Acetylcellulose
DE10126924A1 (de) * 2001-06-01 2002-12-05 Boehringer Ingelheim Pharma Inhalationskapseln
US20040043064A1 (en) * 2002-08-29 2004-03-04 Iorio Theodore L. Dosage forms having reduced moisture transmission

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT941426B (it) 1971-07-17 1973-03-01 Isf Spa Inalatore a camera di turbinio per sostanze medicamentose polveriformi
US4069819A (en) 1973-04-13 1978-01-24 Societa Farmaceutici S.P.A. Inhalation device
IT1016489B (it) 1974-03-18 1977-05-30 Isf Spa Inalatore
DE3345722A1 (de) 1983-12-17 1985-06-27 Boehringer Ingelheim KG, 6507 Ingelheim Inhalator
DE3927170A1 (de) 1989-08-17 1991-02-21 Boehringer Ingelheim Kg Inhalator
DE9013901U1 (de) 1990-10-05 1990-12-20 Hoechst Ag, 6230 Frankfurt Arzneimittelverpackung mit Kappenverschluß
DE4318455A1 (de) 1993-06-03 1994-12-08 Boehringer Ingelheim Kg Kapselhalterung
PT101450B (pt) 1994-02-02 1999-11-30 Hovione Produtos Farmaceuticos Novo dispositivo para inalacao
PT101988B (pt) 1997-04-04 2004-02-27 Hovione Farmaciencia Sa Sistema de orientacao e posicionamento de um objecto
DE19733651A1 (de) 1997-08-04 1999-02-18 Boehringer Ingelheim Pharma Wässrige Aerosolzubereitungen enthaltend biologisch aktive Markomoleküle und Verfahren zur Erzeugung entsprechender Aerosole
GB9805102D0 (en) 1998-03-10 1998-05-06 Ciba Geigy Ag Device
DE19835346A1 (de) 1998-08-05 2000-02-10 Boehringer Ingelheim Pharma Zweiteilige Kapsel zur Aufnahme von pharmazeutischen Zubereitungen für Pulverinhalatoren
NZ514442A (en) 1999-03-03 2003-08-29 Optinose As Nasal delivery device
DE102005022862A1 (de) 2005-05-18 2006-12-14 Airsec S.A.S Kapseln für Inhalatoren

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE605541C (de) * 1926-05-09 1934-11-13 August Adolf Dulitz Verfahren zur Herstellung von Schrumpfkapseln aus Acetylcellulose
DE10126924A1 (de) * 2001-06-01 2002-12-05 Boehringer Ingelheim Pharma Inhalationskapseln
US20040043064A1 (en) * 2002-08-29 2004-03-04 Iorio Theodore L. Dosage forms having reduced moisture transmission

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
BAUER, K.H., FRÖMMING, K.-H., FÜHRER, C.: "Pharmazeutische Technologie", 1993, GEORG THIEME VERLAG STUTTGART, STUTTGART, ISBN: 3-13-692504-1, XP002519951 *

Also Published As

Publication number Publication date
DE102007052871A1 (de) 2009-05-07

Similar Documents

Publication Publication Date Title
EP2007458B1 (fr) Inhalateur
EP2254630A1 (fr) Inhalateurs de poudre
EP2007459A1 (fr) Inhalateur
EP2066382B1 (fr) Doseur à piston
EP1948274B1 (fr) Aiguille pour percer des capsules de poudre pour l'inhalation
EP2004262A2 (fr) Magasin à médicaments pour inhalateur, et inhalateur à poudre à doses multiples
EP2007349B1 (fr) Formulations de suspensions pour aérosols utilisant du tg 227 ea ou du tg 134 a comme propulseur
WO2007118801A1 (fr) Inhalateur
EP2066380A2 (fr) Inhalateur
EP2001601B1 (fr) Aérosols de dosage pour l'administration de préparations pharmaceutiques
WO2007048763A1 (fr) Inhalateur avec embout ayant une fonction de protection microbiologique
EP2170730A1 (fr) Nouvel agent pharmaceutique poudreux contenant du tiotropium et du salmétérol ainsi que du lactose en tant qu'agent auxiliaire
EP2091571B1 (fr) Procédé de stérilisation d'un récipient en feuille
EP2004261B1 (fr) Dispositif de distribution de médicaments
DE102007036412A1 (de) Prüfvorrichtung
WO2009056603A1 (fr) Capsule destinée à contenir des formulations de principes actifs pharmaceutiques
WO2009098083A1 (fr) Procédé et dispositif pour remplir des gélules
WO2007048764A2 (fr) Absorption du gaz propulseur d'aerosols-doseurs pourvus d'emballages
EP1919549A1 (fr) Systeme transcorneen permettant de delivrer une substance active medicamenteuse
EP2001536A1 (fr) Emballage pour inhalateur de poudre multidose avec proprietes optimisees de purge
EP2007649A1 (fr) Capsule en métal en deux parties, destinée à contenir des préparations pharmaceutiques pour inhalateurs à poudre
EP2198972A1 (fr) Réservoir et gicleur

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08844072

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08844072

Country of ref document: EP

Kind code of ref document: A1